Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 15/20 | 0.50 |
| ▸ | THRA | P10827 | 13/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105557 | 0.89 | THRA (0.65) | THRBTHRALMNA | |
| SCHEMBL5115594 | 0.89 | THRB (0.50) | THRBTHRALMNAALDH1A1RXRA | |
| SCHEMBL5108768 | 0.89 | PPARD (0.46) | THRBTHRALMNANR2E1PPARD | |
| SCHEMBL4922875 | 0.89 | THRB (0.52) | THRBTHRAPPARDRXRARXRB | |
| SCHEMBL5118031 | 0.88 | THRB (0.47) | THRBTHRALMNAALDH1A1 | |
| SCHEMBL5104439 | 0.88 | THRA (0.47) | THRBTHRALMNANR2E1ALDH1A1 | |
| SCHEMBL4930845 | 0.88 | THRB (0.49) | THRBTHRAPPARD | |
| SCHEMBL4930674 | 0.87 | THRB (0.53) | THRBTHRAPPARDRXRARXRB | |
| SCHEMBL4932092 | 0.86 | THRB (0.51) | THRBTHRARXRARXRBRXRG | |
| SCHEMBL5112643 | 0.85 | THRA (0.44) | THRBTHRALMNANR2E1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | KARO BIO AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1732532-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092316-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885LMNA 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.